Single-port and multi-port RARP approaches were found to provide similar 1-year biochemical recurrence rates. The generative AI model ChatGPT was fed a prostate cancer risk stratification algorithm. The primary outcome was the potential for focal or hemi-gland ablation following analysis of the final pathologic specimen. New research sheds light on the safety of (177Lu)–PSMA-617 for patients with mCRPC and poor bone marrow reserve. Dr. Madan describes the background for the PARPi approvals stemming from recent studies and the ongoing issues with them. A poster reported on AEs occurring after Lu-PSMA treatment, as well as variables associated with ER visits. Compared with ADT alone, apalutamide plus ADT had a favorable hazard ratio across all end points regardless of age. There was a 57% increase in the number of non-European prostate cancer cases compared to previous association studies. The FDA approved enzalutamide as the first AR-signaling inhibitor for the treatment of nmCSPC with high-risk BCR. The panel shares insights on future advancements in the field. The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023. The panel discusses treatment-related adverse events, including hematologic toxicities, xerostomia, and more. The panel discuss patient interest in receiving radioligand therapy in the context of cost and access challenges. The panel discusses results of the phase 3 PSMAfore study presented at ESMO 2023. The panel talks "pearls of wisdom" with radioligand therapy. The panel discusses recommended frequency of scans for patients receiving radioligand therapy, PSA response, and more. The panel discussed initial access issues with radioligand therapy, as well as interdisciplinary team collaboration. A single priming dose of 177Lu-PSMA-617 followed by pembrolizumab maintenance was found to be a safe treatment for mCRPC. PCSM was found to be lower after local therapy use in patients with higher-risk disease, particularly after RP. Clarity announced that 50 patients have now been imaged with 64Cu-SAR-Bombesin in its US-based diagnostic trial.